Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GCK | P35557 | 2/20 | 0.45 |
| ▸ | GCKR | Q14397 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5748224 | 0.88 | HTT (0.52) | PTGDRMEN1KMT2AGCKGCKR | |
| SCHEMBL5745816 | 0.85 | LMNA (0.45) | PPARDPPARAPTGDRMEN1KMT2A | |
| SCHEMBL6346332 | 0.84 | ALDH1A1 (0.52) | PTGDRMEN1KMT2AGCKPTPN11 | |
| SCHEMBL6356232 | 0.84 | PTGDR (0.48) | PTGDRMEN1KMT2APTPN11MAPT | |
| SCHEMBL5750620 | 0.84 | PTGDR (0.52) | PTGDRMEN1KMT2APTPN11MAPT | |
| SCHEMBL5487074 | 0.83 | KDM4E (0.59) | PPARDPPARAMEN1KMT2AGCK | |
| SCHEMBL5747012 | 0.83 | PTGDR (0.53) | PTGDRMEN1KMT2APTPN11MAPT | |
| SCHEMBL5747078 | 0.83 | MEN1 (0.66) | MEN1KMT2APTPN11MAPTATM | |
| SCHEMBL6349175 | 0.82 | HSD11B1 (0.61) | PTGDRMEN1KMT2AGCKGCKR | |
| SCHEMBL6349243 | 0.82 | DRD2 (0.46) | PTGDRMEN1KMT2AMAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735280-A1 | ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS | Kalypsys, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005115983-A1 | ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS | KALYPSYS, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | KALYPSYS, INC. (US) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885PTGDR 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.